# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Milken Conference
As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on th...
A weaker-than-expected jobs report sparked a widespread market rally in the last session of the week, as traders increased expe...
RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $332 to $...